Interferon free therapy with direct acting antivirals for HCV
- 3 January 2013
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 33 (s1), 93-104
- https://doi.org/10.1111/liv.12076
Abstract
The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross-resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.This publication has 23 references indexed in Scilit:
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1The New England Journal of Medicine, 2012
- The NS5A Replication Complex Inhibitors: Difference Makers?Clinics in Liver Disease, 2011
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinJournal of Hepatology, 2009
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796Antimicrobial Agents and Chemotherapy, 2009
- Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CGut, 2007
- BILN 2061: a major step toward new therapeutic strategies in hepatitis CJournal of Hepatology, 2004
- Fibrosis and disease progression in hepatitis CJournal of Hepatology, 2002
- Fibrosis and disease progression in hepatitis CJournal of Hepatology, 2002
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989